Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 8/20 | 0.49 |
| ▸ | RXRA | P19793 | 12/20 | 0.46 |
| ▸ | RARB | P10826 | 8/20 | 0.41 |
| ▸ | RARG | P13631 | 8/20 | 0.41 |
| ▸ | RARA | P10276 | 6/20 | 0.40 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | RXRG | P48443 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239783 | 0.81 | HNF4A (0.72) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6239181 | 0.78 | RXRA (0.55) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6273432 | 0.77 | HNF4A (0.57) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6239175 | 0.75 | RXRA (0.67) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6240826 | 0.72 | RXRA (0.58) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6240820 | 0.71 | RXRA (0.49) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6273701 | 0.71 | HNF4A (0.60) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6243135 | 0.70 | RXRA (0.53) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6239279 | 0.70 | RXRA (0.58) | HNF4ARXRARARBRARGRARA | |
| SCHEMBL6243129 | 0.68 | RXRA (0.55) | HNF4ARXRARARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005017185-A2 | HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS | LIGAND PHARMCEUTICALS INCORPORATED (US) | 2005-02-24 | — | — | WO | disclosed |